Log in

Gilead Sciences Stock Price, Forecast & Analysis (NASDAQ:GILD)

$64.29
-0.78 (-1.20 %)
(As of 11/19/2019 06:17 AM ET)
Today's Range
$63.72
Now: $64.29
$65.17
50-Day Range
$61.65
MA: $64.12
$66.48
52-Week Range
$60.32
Now: $64.29
$72.90
Volume6.16 million shs
Average Volume6.20 million shs
Market Capitalization$81.34 billion
P/E Ratio10.45
Dividend Yield3.87%
Beta1.09
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.13 billion
Cash Flow$7.24 per share
Book Value$16.65 per share

Profitability

Net Income$5.46 billion

Miscellaneous

Employees11,000
Outstanding Shares1,265,150,000
Market Cap$81.34 billion
Next Earnings Date2/3/2020 (Estimated)
OptionableOptionable

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.


Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, October 24th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.63 per share on Monday, December 30th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date of this dividend is Thursday, December 12th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, October, 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.01. The biopharmaceutical company earned $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company's quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the business earned $1.84 earnings per share. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

25 brokerages have issued 1-year target prices for Gilead Sciences' shares. Their forecasts range from $60.00 to $95.00. On average, they expect Gilead Sciences' share price to reach $79.32 in the next year. This suggests a possible upside of 23.4% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 1 sell rating, 8 hold ratings, 14 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. Needham & Company LLC analysts commented, "Gilead reported $5.28B in 1Q19 total revenue, in line w/ our $5.27B and consensus $5.3B ests. Product sales were $5.20B (-8% q/q), matching our $5.16B and consensus $5.2B ests. Mgmt had guided for 12-14% sequential decline. All annual guidance unch. Non-GAAP EPS $1.76 was above our $1.64 and consensus $1.61 ests. New CEO O’Day outlined priorities (Strengthen pipeline [internal and external business development]; Ensure optimal commercial delivery; and Reassess organizational structure [‘evolution not revolution’]) and announced that Kite will operate as a separate business unit w/ a new CEO reporting directly to O’Day. Filgotinib MAA to be submitted 3Q19, but no update yet on strategy/ timing for NDA submission. NASH ATLAS drug combination trial results expected 4Q19 (unch). HOLD." (5/6/2019)
  • 2. Cowen Inc analysts commented, "NTLA reported 1Q results of $10.4M in collaboration revenue, $34M in -$0.49 vs consensus EPS of -$0.57. 1Q cash balance was $296.6M, which management estimates will fund operations into 1H 2021. The call included several updates on the pipeline in in-vivo editing and ex-vivo engineered T-Cells: 1) NTLA remains on track for NDA submission of NTLA-2001 for ATTR in 2020 and preparations (manufacturing & toxicology) are ongoing. 2) Data presented at ASGCT was the first demonstration of CRISPR/Cas9-based targeted insertion in the liver of non-human primates. We view this as a validation of NTLA’s modular LNP+AAV approach to in-vivo editing. 3) ASGCT presentation on engineered cell therapy (WT1 insertion into >95% of isolated T-cells) shows progress in cell therapy." (5/3/2019)
  • 3. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past three months." (5/2/2019)
  • 4. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy." (4/25/2019)
  • 5. Mizuho analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (4/22/2019)

Has Gilead Sciences been receiving favorable news coverage?

News headlines about GILD stock have trended extremely negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gilead Sciences earned a news sentiment score of -4.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Gilead Sciences.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 14,920,000 shares, an increase of 7.2% from the September 30th total of 13,920,000 shares. Based on an average daily volume of 5,970,000 shares, the short-interest ratio is presently 2.5 days. Currently, 1.2% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Celgene (CELG), Alibaba Group (BABA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Netflix (NFLX), NVIDIA (NVDA), AT&T (T), Bank of America (BAC) and Starbucks (SBUX).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
  • Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
  • Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
  • Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
  • Mr. Daniel O'Day, Chairman & CEO (Age 55)

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Parnassus Investments CA (0.80%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), California Public Employees Retirement System (0.27%), Russell Investments Group Ltd. (0.20%), First Trust Advisors LP (0.19%) and Candriam Luxembourg S.C.A. (0.18%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John Francis Cogan, Olsen Per Wold, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Banco Santander S.A., State of New Jersey Common Pension Fund D, First Trust Advisors LP, Mondrian Investment Partners LTD, Artemis Investment Management LLP, Assenagon Asset Management S.A., DNB Asset Management AS and Miller Howard Investments Inc. NY. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Gayle E Wilson, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences.

Which major investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Railway Pension Investments Ltd, Cambiar Investors LLC, California Public Employees Retirement System, Envestnet Asset Management Inc., PGGM Investments, Hamlin Capital Management LLC and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $64.29.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $81.34 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe.View Additional Information About Gilead Sciences.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is http://www.gilead.com/.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  2,162 (Vote Outperform)
Underperform Votes:  1,046 (Vote Underperform)
Total Votes:  3,208
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel